The Conversation (0)
Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19
Apr. 02, 2020 05:47AM PST
Pharmaceutical Investing
Algernon Pharmaceuticals Inc. (CSE:AGN) is pleased to announce that the protocol for a planned physician initiated phase 2 clinical study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea has been finalized.
Algernon Pharmaceuticals Inc. (CSE:AGN) (FRANKFURT:AGW) (OTCQB:AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the protocol for a planned physician initiated phase 2 clinical study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea has been finalized. The Company also wishes to advise that all ethics submission documents are near completion and submission for study approval is expected to occur shortly.
The Ifenprodil COVID-19 study will be supported by the Company and by Novotech, an internationally recognized full service CRO known for its experience across Australia, New Zealand, Asia and South Africa.
The Company is also pleased to report that it has retained Novotech to conduct an additional Ifenprodil phase 2 COVID-19 human trial in Australia, which will be Company sponsored. The decision was made to move forward with a second COVID-19 study based on the results of a recently conducted successful feasibility study. The Company is working to prepare all documentation for an ethics approval submission in Australia, which will be filed shortly.
“We have been advised by our regulatory experts that submissions for ethics approval for COVID-19 related human trials are being reviewed on an expedited basis in most jurisdictions,” said Christopher J. Moreau CEO of Algernon. “The Algernon and Novotech clinical development teams have worked tirelessly on the Company’s COVID-19 clinical trial program and have compressed processes that usually take many months, into days and weeks.”
About NP-120 (Ifenprodil)
NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NDMA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. Although the anti-fibrotic activity of Ifenprodil in IPF is not known, recent studies have suggested a link between both receptors and pathways associated with fibrosis.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
The Company cautions that it is in the early stages of clinical research and development and is not making any express or implied claims that NP-120 (Ifenprodil) is an effective treatment for the COVID-19 virus at this time.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
